| |
Redefine what it means to be inspection-ready with Premier’s Inspection Readiness Program. This four-phase plan will arm you with the knowledge, skills, and confidence to successfully host health authority inspections. Get started with our brochure.
|
|
Today’s Big NewsOct 25, 2024 |
|
The deal will help Jubilant Biosys expand its footprints in Europe for drug discovery and pre-clinical offerings in areas like biologics and ADC on top of existing integrated drug discovery services & CDMO from India.
|
|
| By Kevin Dunleavy South San Francisco-based Septerna has scored with an upsized initial public offering of $288 million, which far exceeded the $157.9 million the company said it expected to generate in an SEC filing early this week. Trading for “SEPN” began on Friday. |
|
|
|
By Nick Paul Taylor GenSight Biologics is weeks away from running out of money. Again. The biotech only has enough cash to fund operations into mid-November and, with a revenue stream set to start later than planned, needs bridge financing to survive. |
By Nick Paul Taylor AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 million upfront to form a new drug discovery pact with Gedeon Richter. |
Sponsored by Travere Therapeutics When a specialized field of medicine has long been quiet, a buzz of breakthrough can seem like a sudden development. The reality is more nuanced. |
|
| 45 markers for cytokine signaling/inflammationTrust RBM for Olink, Luminex & Simoa immunoassays
|
|
By Fraiser Kansteiner In the phase 1/1b ARC-20 study of Arcus’ candidate casdatifan in metastatic clear cell renal cell carcinoma, the biotech’s HIF-2a inhibitor achieved a confirmed overall response rate (ORR) of 25%. Analysts at Evercore ISI were optimistic about Arcus’ data and the candidate's prospects against an approved rival. |
Sponsored by TriNetX, Inc. Now’s the time to rethink clinical trials with real-world data (RWD). Discover strategies to optimize your protocols and site selection. |
By Kevin Dunleavy Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline. It licensed ALXN-1840, a candidate for the treatment of Wilson disease that was previously considered promising enough that Alexion, now an AZ subsidiary, paid $855 million to acquire it six years ago. |
By Darren Incorvaia Poseida Therapeutics’ gene therapy for hereditary angioedema reduced kallikrein protein activity in a mouse model of the disease and edited a gene in the livers of nonhuman primates, the company said in an Oct. 24 release. |
By Fraiser Kansteiner In its biggest U.S. manufacturing investment yet, GSK is spending up to $800 million to double the size and capacity of its site in Marietta, Pennsylvania. The upgraded manufacturing campus will be equipped to crank out commercial drugs and vaccines plus medicines for clinical trials. |
By Darren Incorvaia,Zoey Becker Shiny new Jade Biosciences has selected its CEO in Tom Frohlich, who co-founded Chinook Therapeutics and served as chief operating operator until it was bought out by Novartis last year. Jade’s new chief medical officer Hetal Kocinsky, M.D., also comes from Chinook, as does the company’s newly appointed board chairman Eric Dobmeier, formally Chinook’s CEO. |
By Angus Liu Astellas' first-in-class CLDN18.2 drug Vyloy has cleared the FDA. After a positive phase 3 readout, Otsuka is targeting an accelerated approval filing for a kidney disease candidate. Samsung Biologics has signed its largest contract from a single customer to date. And more. |
By Ayla Ellison,Conor Hale This week on "The Top Line," Fierce Medtech's Conor Hale dives into EY's 18th annual Pulse of the MedTech Industry report and chats with EY's John Babbitt about the team's findings and the pace of M&A, venture capital funding and recent IPOs. |
By Heather Landi Baxter International said Thursday it anticipates restarting its highest-throughput IV solutions manufacturing line within the next week. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Medtech's Conor Hale dives into EY's 18th annual Pulse of the MedTech Industry report and chats with EY's John Babbitt about the team's findings and the pace of M&A, venture capital funding and recent IPOs. |
|
|---|
|
|
| WhitepaperDiscover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
| eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
| WhitepaperTake a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
| WhitepaperUnlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
